Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcus Biosciences (RCUS) Liabilities and Shareholders Equity (2017 - 2025)

Historic Liabilities and Shareholders Equity for Arcus Biosciences (RCUS) over the last 9 years, with Q3 2025 value amounting to $974.0 million.

  • Arcus Biosciences' Liabilities and Shareholders Equity fell 2507.69% to $974.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.4 billion, marking a year-over-year decrease of 1103.17%. This contributed to the annual value of $1.2 billion for FY2024, which is 502.28% up from last year.
  • Per Arcus Biosciences' latest filing, its Liabilities and Shareholders Equity stood at $974.0 million for Q3 2025, which was down 2507.69% from $1.1 billion recorded in Q2 2025.
  • Over the past 5 years, Arcus Biosciences' Liabilities and Shareholders Equity peaked at $1.6 billion during Q4 2021, and registered a low of $839.3 million during Q3 2021.
  • For the 5-year period, Arcus Biosciences' Liabilities and Shareholders Equity averaged around $1.2 billion, with its median value being $1.2 billion (2024).
  • As far as peak fluctuations go, Arcus Biosciences' Liabilities and Shareholders Equity skyrocketed by 43088.33% in 2021, and later crashed by 2507.69% in 2025.
  • Quarter analysis of 5 years shows Arcus Biosciences' Liabilities and Shareholders Equity stood at $1.6 billion in 2021, then decreased by 18.34% to $1.3 billion in 2022, then fell by 15.77% to $1.1 billion in 2023, then rose by 5.02% to $1.2 billion in 2024, then fell by 15.3% to $974.0 million in 2025.
  • Its Liabilities and Shareholders Equity stands at $974.0 million for Q3 2025, versus $1.1 billion for Q2 2025 and $1.2 billion for Q1 2025.